UB-BJ02 also modulated Alzheimer’s disease risk molecules by decreasing the expression of triggering receptor expressed on myeloid cells 2 (TREM2) and increasing cluster of differentiation 33 (CD33). This evidence concerns the gene TREM2 and Alzheimer disease.